I am hoping the try the clinical stage route and pay royalties for use of a CI in the next reiteration of Direct. Somehow my comments were interpreted as though Direct is not working at all. I just think they have a lot to prove to get regulatory approval, and phase I so far revealed (SD achieved for short duration) they may need to go to a large blinded control study to get approval (if they never get 30% of study participants shrinkage). If adding a checkpoint inhibitor early on can allow the vaccine more on an opportunity to decrease the inoperable tumor mass, then I believe they should go that route. If successful, they can avoid a blinded study. But I do think they were trying to partner on Direct. They announced it last February that they were talking about it. My views is they initiated the discussions, but it's a "stay tuned" kind of thing. I've tuned out. :)
Market Data 
Markets 
AI
